258 related articles for article (PubMed ID: 17062688)
1. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
3. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression.
Liu QY; Stein CA
Clin Cancer Res; 1997 Nov; 3(11):2039-46. PubMed ID: 9815595
[TBL] [Abstract][Full Text] [Related]
4. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
5. Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
DiPaola RS; Aisner J
Semin Oncol; 1999 Feb; 26(1 Suppl 2):112-6. PubMed ID: 10190792
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
[TBL] [Abstract][Full Text] [Related]
9. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
11. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Zhang HL; Yang LF; Zhu Y; Yao XD; Zhang SL; Dai B; Zhu YP; Shen YJ; Shi GH; Ye DW
Prostate; 2011 Feb; 71(3):326-31. PubMed ID: 20842666
[TBL] [Abstract][Full Text] [Related]
12. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.
Hahm ER; Arlotti JA; Marynowski SW; Singh SV
Clin Cancer Res; 2008 Feb; 14(4):1248-57. PubMed ID: 18281560
[TBL] [Abstract][Full Text] [Related]
13. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
14. [The expression of Bcl-2, Bcl-xl, Bak and Bax proteins in axons of the optic nerve in closed-angle glaucoma].
Zalewska R; Reszeć J; Mariak Z; Sulkowski S
Klin Oczna; 2004; 106(1-2 Suppl):155-7. PubMed ID: 15510481
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.
Nakano Y; Bilim V; Yuuki K; Muto A; Kato T; Nagaoka A; Tomita Y
Prostate Cancer Prostatic Dis; 2009; 12(1):34-40. PubMed ID: 18475287
[TBL] [Abstract][Full Text] [Related]
17. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy.
Kang SY; Han JH; Lee KJ; Choi JH; Park JI; Kim HI; Lee HW; Jang JH; Park JS; Kim HC; Kang S; Oh YT; Chun M; Kim JH; Sheen SS; Lim HY
Clin Cancer Res; 2007 Jul; 13(14):4146-53. PubMed ID: 17634542
[TBL] [Abstract][Full Text] [Related]
18. Approaches to the treatment of patients with hormone-sensitive prostate cancer.
DiPaola RS
Semin Oncol; 1999 Oct; 26(5 Suppl 17):24-7. PubMed ID: 10604265
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms.
Schweitzer M; Mitmaker B; Obrand D; Sheiner N; Abraham C; Dostanic S; Chalifour LE
Can J Physiol Pharmacol; 2009 Nov; 87(11):915-22. PubMed ID: 19935899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
